CONCEPT AND MANAGEMENT OF PREMENSTRUAL SYNDROME (MUTLAZIMA QABL HAIZ ) IN UNANI SYSTEM OF MEDICINE

  • Sofia Naushin Research Associate, CCRUM, Ministry of Ayush, Govt. of India.
  • Mubarak Ali Research Associate, CCRUM, Ministry of Ayush, Govt. of India.
  • Dr Mustehasan Research Officer, CCRUM, Ministry of Ayush, Govt. of India.

Abstract

Mutlazima Qabl Haiz (Premenstrual syndrome) refers to a combination of physical and emotional disturbances that occur after a woman ovulates and resolves with start of menstruation. More than 200 symptoms have been ascribed to PMS. Premenstrual Dysphoric Disorder ia a more severe form of premenstrual syndrome. The characteristic symptoms of premenstrual syndrome are mood swings, anxiety, and irritability and physical conditions – like headache, fatigue, bloating, sleep disturbances, nausea, and breast tenderness. 90% of the women all over the world experience these symptoms during their reproductive years. The PMS has unknown cause and does not have any specific proved diagnosis and medication in modern medicine. The main objective of this article is to review the potential treatment for premenstrual syndrome in unani medicine.


Keywords: Premenstrual Syndrome, Premenstrual Dysphoric Syndrome, Unani Management

Downloads

Download data is not yet available.

Author Biographies

Sofia Naushin, Research Associate, CCRUM, Ministry of Ayush, Govt. of India.

Research Associate, CCRUM, Ministry of Ayush, Govt. of India.

Mubarak Ali, Research Associate, CCRUM, Ministry of Ayush, Govt. of India.

Research Associate, CCRUM, Ministry of Ayush, Govt. of India.

Dr Mustehasan, Research Officer, CCRUM, Ministry of Ayush, Govt. of India.

Research Officer, CCRUM, Ministry of Ayush, Govt. of India.

References

1. Wyatt K (1999) Efficacy of vitamin B6 in the treatment of premenstrual syndrome: Systematic review. BMJ 318: 1375-1381.
2. Hantsoo L, Epperson CN. Premenstrual Dysphoric Disorder: Epidemiology and Treatment. Curr Psychiatry Rep. 2015 Nov;17(11):87.
3. Johnson SR. Premenstrual Syndrome, Premenstrual Dysphoric Disorder and Beyond: A Clinical Primer for Practitioners. Obstet Gynecol 2004; 104 (4):845-59.
4. Sternfeld B, Swindle R, Chawla A, Long S, Kennedy S. Severity of Premenstrual Symptoms in a Health Maintenance Organization Population. Obstet Gynecol 2002 Jun; 99(6):1014-24.
5. Cheng SH et al.: Perception of premenstrual syndrome and attitude of evaluations of work performance among incoming university female students. Biomed J. 2015, Mar-Apr; 38:167-72.
6. Shershah S, Morrison JJ, Jafarey S. Prevalence of premenstrual syndrome in Pakistani women . J Pak Med Assoc. 1991 May; 41(5):101-3.
7. Copeland LJ, Jarrell JF, McGregor JA. Textbook of Gynaecology. Philadelphia: WB Saunders Company; 1993: 403-413.
8. www.languagesource.com/acatolog/Arabic_Translation_Software_Arabic_Al_Wafi.html. cited on 27.06.16.
9. Anonymous. The Unified Medical Dictionary. Eng-Ara-Fren.3rd ed. Switzerland: Council of Arab ministers of health; 1983:642.
10. IbnSina. Al Qanoon Fil Tib. Vol II. (Urdu Translation by Kantori GH). New Delhi: Idarae Kitabus Shifa; 1981: 331-345.
11. Zakari Razi.(2001) Kitaul Havi Vol 9th. New Delhi; CCRUM .p.151-168.
12. Ghulam Jeelani. Makhzan-e-Hikmat, Vol II, Mufeed Aam Press, Lahore. 1933: p-1928-1932.
13. Ajmal khan. (1983) Hazique New Delhi Jaseen Book Depo: p. 461-471.
14. Emans SJ, Laufer MR, Goldstein DP. Premenstrual syndrome. Pediatric and Adolescent Gynecology. 5th ed. Philadelphia, PA: Lippincott-Raven Inc; 2005. 461-467.
15. Cunningham J, Yonkers KA, O'Brien S, Eriksson E. Update on research and treatment of premenstrual dysphoric disorder. Harv Rev Psychiatry, 2009;17(2):120-137.
16. Khajehei M1, Abdali K, Parsanezhad ME, Tabatabaee HR. Effect of treatment with dydrogesterone or calcium plus vitamin D on the severity of premenstrual syndrome. Int J Gynaecol Obstet. 2009 May;105(2):158-161.
17. Roger P. smith. Gynaecology in primary care. Philadelphia: Williams and Wilkins; 1997: 427-441.
18. Paula K. B., Mini-Review: Premenstrual Syndrome and Premenstrual, Dysphoric Disorder. Journal of Pediatric and Adolescent Gynecology. 2007; 20:3-12
19. Brian Magowan Philip Owen Andrew Thomson. Clinical Obstetrics and Gynecology 3rd Edition; 2014.
20. Lustyk MK, Gerrish WG, Shaver S, Keys SL. Cognitive-behavioral therapy for premenstrual syndrome and premenstrual dysphoric disorder: a systematic review. Arch Womens Ment Health. 2009; Apr 12(2):85-96.
21. Elena A.Q. , Ghassan A.Q., Does Vitamin D and Calcium Affect the Incidence of Premenstrual Syndrome, World family medicine journal. 2010;7(10).
22. American College of Obstetricians and Gynecologists. ACOG practice bulletin no. 15: Premenstrual syndrome. Obstet Gynecol. 2000 Apr ;95(4).
23. Brown J, O’Brien PM, Marjoribanks J, Wyatt K. Selective Serotonin Reup¬take Inhibitors for Premenstrual Syndrome. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD001396.
24. Yonkers KA et al. Efficacy of a New Low-Dose Oral Contraceptive With Drospirenone in Premenstrual Dysphoric Disorder. Obstet Gynecol. 2005 Sep;106(3):492-501.
25. Lopez L, Kaptein A, Helmerhorst FM. Oral Contraceptives Containing Drospirenone for Premenstrual Syndrome. Cochrane Database Syst Rev. 2008 Jan 23;(1):CD006586.
26. Rapkin A. A Review of Treatment of Premenstrual Syndrome & Premenstrual
Dysphoric Disorder. Psychoneuroendocrinology. 2003 Aug; 28 Suppl 3:39-53.
27. O’Brien PM, Abukhalil IE. Randomized Controlled Trial of the Management of Premenstrual Syndrome and Premenstrual Mastalgia using Luteal Phase-Only Danazol. Am J Obstet Gynecol 1999 Jan;180(1 pt 1):18-23.
28. Wyatt K, Dimmock PW, O’Brien PM. Premenstrual syndrome. In: Clinical evidence. Barton S, ed. 4th issue. London: BMJ Publishing Group, 2000:1121-33.
29. Ward M, Holimon T. Calcium Treatment for Premenstrual Syndrome. Ann Pharmacother 1999 Dec; 33 (12):1356-1358.
30. Shamberger RJ. Calcium, magnesium, and other elements in the red blood cells and hair of normals and patients with premenstrual syndrome. Biol Trace Elem Res. 2003 Aug;94(2):123-9.
31. Bendich A. The Potential for Dietary Supplements to Reduce Premenstrual Syndrome (PMS) Symptoms. J Am Coll Nutr. 2000 Feb;19(1):3-12.
32. Loch E, Selle H, Boblitz N. Treatment of Premenstrual Syndrome with a Phytopharmaceutical Formulation Containing Vitex agnus castus. J Womens Health Gend Based Med. 2000 Apr;9(3):315-20.
33. Szegedi A, Kohnen R, Dienel A, Kieser M. Acute Treatment Of moderate to Severe Depression with Hypericum Extract WS 5570 (St John's wort): Randomised Controlled Double Blind Non-inferiority Trial versus Paroxetine. BMJ. 2005 Mar 5;330(7490):503. Epub 2005 Feb 11.
34. Liu J et al. Evaluation of Estrogenic Activity of Plant Extracts for the Potential Treatment of Menopausal Symptoms. J Agric Food Chem. 2001 May;49(5):2472-9.
35. Navarro V et al. Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology. 2014 Oct;60(4):1399-408. doi: 10.1002/hep.27317. Epub 2014 Aug 25.
36. Paula K. B., Mini-Review: Premenstrual Syndrome and Premenstrual, Dysphoric Disorder. Journal of Pediatric and Adolescent Gynecology. 2007; 20:3-12.
Statistics
39 Views | 37 Downloads
How to Cite
Naushin, S., Ali, M., & Mustehasan, D. (2018). CONCEPT AND MANAGEMENT OF PREMENSTRUAL SYNDROME (MUTLAZIMA QABL HAIZ ) IN UNANI SYSTEM OF MEDICINE. Journal of Drug Delivery and Therapeutics, 8(5-s), 122-125. https://doi.org/10.22270/jddt.v8i5-s.1992
Section
Review